Innovation Pharmaceuticals Inc (IPIX)

[Patientspeople]

Celgene Opts Out of Licensing Option For OncoMed's Navicixizumab
BY MT Newswires
— 9:08 AM ET 09/20/2018
09:08 AM EDT, 09/20/2018 (MT Newswires) -- OncoMed Pharmaceuticals ( OMED)said Thursday that Celgene ( CELG ) has decided not to exercise its option to license the bispecific antibody navicixizumab and said both companies were working to formalize the termination of the collaboration agreement.
OncoMed said it expects to retain worldwide rights to navicixizumab and is currently conducting a phase 1b clinical trial in combination with paclitaxel in patients with platinum-resistant late-stage ovarian cancer.
Celgene ( CELG ) continues to retain its options to license OncoMed's etigilimab and rosmantuzumab under the collaboration.
Price: 2.80, Change: -0.11, Percent Change: -3.78
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.


Intersting timing IMO